Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

About this update from Rhythm Pharmaceuticals, Inc.

[{"type":"image","alt":"Rhythm Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Rhythm Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/diOYkE69oi1YPSL0HU1OAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c","width":300,"height":105}},"lazy":false},{"type":"text","content":"BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Tuesday, May 5, 2026 to report its first quarter 2026 financial results and provide a corporate update.","length":416,"tagName":"p"},{"type":"text","content":"Also today, Rhythm announced that Hunter Smith, Chief Financial Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:00 a.m. ET.","length":227,"tagName":"p"},{"type":"text","content":"Live webcasts of both the financial results conference call and the fireside chat will be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at http://ir.rhythmtx.com/. The archived webcast of the financial results conference call will be available on Rhythm’s website approximately two hours after it concludes and will be available for 30 days following the call. A replay of the Needham Virtual Healthcare Conference webcast will also be available on the Rhythm website for 30 days following the presentation.","length":586,"tagName":"p"},{"type":"text","content":"About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long ...

More updates from Rhythm Pharmaceuticals, Inc.